This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whitehead, S. S.
Right arrow Articles by Murphy, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitehead, S. S.
Right arrow Articles by Murphy, B. R.

 Previous Article  |  Next Article 

Journal of Virology, April 1999, p. 3438-3442, Vol. 73, No. 4
0022-538X/99

Recombinant Respiratory Syncytial Virus Bearing a Deletion of either the NS2 or SH Gene Is Attenuated in Chimpanzees

Stephen S. Whitehead,1,* Alexander Bukreyev,1 Michael N. Teng,1 Cai-Yen Firestone,1 Marisa St. Claire,2 William R. Elkins,3 Peter L. Collins,1 and Brian R. Murphy1

Respiratory Viruses Section1 and Experimental Primate Virology Section,3 Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892, and Bioqual, Inc., Rockville, Maryland 208502

Received 13 November 1998/Accepted 7 January 1999


    ABSTRACT
Top
Abstract
Text
References

The NS2 and SH genes of respiratory syncytial virus (RSV) have been separately deleted from a recombinant wild-type RSV strain, A2 (M. N. Teng and P. L. Collins, J. Virol. 73:466-473, 1998; A. Bukreyev et al., J. Virol. 71:8973-8982, 1997; and this study). The resulting viruses, designated rA2Delta NS2 and rA2Delta SH, were administered to chimpanzees to evaluate their levels of attenuation and immunogenicity. Recombinant virus rA2Delta NS2 replicated to moderate levels in the upper respiratory tract, was highly attenuated in the lower respiratory tract, and induced significant resistance to challenge with wild-type RSV. The replication of rA2Delta SH virus was only moderately reduced in the lower, but not the upper, respiratory tract. However, chimpanzees infected with either virus developed significantly less rhinorrhea than those infected with wild-type RSV. These findings demonstrate that a recombinant RSV mutant lacking either the NS2 or SH gene is attenuated and indicate that these deletions may be useful as attenuating mutations in new, live recombinant RSV vaccine candidates for both pediatric and elderly populations. The Delta SH mutation was incorporated into a recombinant form of the cpts248/404 vaccine candidate, was evaluated for safety in seronegative chimpanzees, and can now be evaluated as a vaccine for humans.


    TEXT
Top
Abstract
Text
References

Respiratory syncytial virus (RSV) remains the leading cause of serious viral bronchiolitis and pneumonia in infants and young children throughout the world and accounts for approximately 90,000 hospitalizations in the United States each year (6, 16, 22). RSV infection is also an important cause of severe respiratory illness in elderly (11-13, 24) and immunocompromised (17, 19, 31) populations. While the significance of RSV as a respiratory pathogen has made development of an effective RSV vaccine a public health priority, such a vaccine does not exist. Toward this goal, our laboratory has sought to develop a live, attenuated RSV vaccine since a live virus vaccine, which mimics natural infection, should induce a balanced cellular and humoral immune response without potentiating disease upon subsequent infection with wild-type (wt) virus (6, 25).

A number of live attenuated RSV vaccine candidates have been evaluated in animals and humans, and the most promising subgroup A vaccine candidates, cpts248/404 and its recombinant counterpart rA2cp248/404, have been shown to possess both temperature-sensitive (ts) and non-ts mutations which contribute to the attenuation of the virus (8, 14, 33, 34). Our approach toward vaccine development is based on the observation that a combination of ts and non-ts attenuating mutations in a single virus yields effective vaccine candidates with increased phenotypic stability, as has been seen for influenza virus (26, 27, 30), parainfluenza virus (18), and poliovirus (2, 28, 32). By evaluating several ts virus lineages derived from cold-passaged (cp) RSV (15), we have identified a sufficient collection of ts attenuating mutations (10, 14, 20, 21, 33) and have recently focused our efforts on the identification of stable, non-ts attenuating mutations suitable for inclusion in candidate vaccine strains (3, 34).

As the prototype of the pneumovirus genus of the family Paramyxoviridae, RSV is an enveloped, negative-sense, single-stranded RNA virus with a genome that is 15,222 nucleotides in length and that encodes 10 subgenomic mRNAs (6). Transcription of viral genes is directed by short, conserved gene start and gene end (GE) cis-acting signals that flank each gene and are separated by intergenic regions of various nucleotide lengths. These mRNAs are translated into 11 known proteins: four nucleocapsid proteins, namely, nucleocapsid N protein, phosphoprotein P, large polymerase subunit L, and transcription elongation factor M2-1; three transmembrane envelope glycoproteins, namely, fusion F protein, attachment G protein, and small hydrophobic SH protein; two nonstructural proteins, NS1 and NS2; the matrix M protein; and the putative negative regulatory factor M2-2. Although each of these proteins has been identified, the specific functions of several proteins, such as NS1, NS2, and SH, have not been determined, although NS1 has been shown to inhibit RNA synthesis (1).

By using the previously described reverse genetics system (5), a recombinant wt RSV, designated rA2, was generated. It contains the previously described 4C leader mutation, a set of four intergenic and noncoding region marker mutations, and a set of six L gene translationally silent restriction site markers, as well as two F gene mutations required to bring the coding region of the recombinant wt clone into agreement with that of the human embryonic kidney (HEK) cell-passaged wt RSV (5, 34). Mutant viruses in which either the NS2 or the SH gene (and its respective transcription signal) was completely deleted from rA2 have been successfully engineered, thus demonstrating the dispensable nature of either gene for replication in tissue culture. For deletion of the NS2 gene (Delta NS2), nucleotides 577 to 1098 were removed, which segment joins the authentic NS1 GE sequence to the complete NS2-N intergenic region (29). For deletion of the SH gene (Delta SH), the ScaI-PacI restriction fragment containing the SH gene was deleted and replaced with a short synthetic DNA, resulting in the removal of nucleotides 4205 to 4623 (Fig. 1). This process introduced a single nucleotide change in the M GE signal, making it identical to that of the wt SH GE signals. It should be noted that the Delta SH virus described here (Fig. 1) is different from the one designated D46/6368, which was described previously (3) and which lacks the six silent L gene restriction sites and the two F gene mutations noted above. In chimpanzees, neither the L gene restriction sites nor the F gene mutations affected the replication of recombinant RSV (34). Also, D46/6368 contains some incidental, heterologous sequence and an unusually long intergenic region at the deletion point. Like their wt recombinant parent, the rA2Delta SH and rA2Delta NS2 viruses contain only authentic transcription signals and intergenic regions. Also, they have the same genetic background as previously described biologically derived and recombinant cpts vaccine candidates and thus can be compared directly with those vaccine candidates.


View larger version (11K):
[in this window]
[in a new window]
  		FIG. 1.   Deletion of the SH gene to generate rA2Delta SH. The map of the negative-sense wt RSV genome is shown (not to scale), as is the sequence illustrating the deletion, which involved nucleotides 4205 to 4623 (arrows). To construct rA2Delta SH, plasmid D50, containing the left-hand end of the genome from the 3' leader region to the end of the M2 gene, was digested with ScaI and PacI and the resulting fragment was replaced with a short double-stranded DNA constructed by hybridizing the two synthetic oligonucleotides ACTCAAATAAGTTAAT and TAACTTATTTGAGT. In the final construction, the deletion extended from the middle of the M GE signal to the middle of the SH GE signal. In the Delta SH genome, compared to its wt recombinant parent, the M GE signal sustained a single nucleotide change (AGTTAATAAAAAA to AGTTAATTAAAAA, with the change underlined) to become identical to that of the wt SH GE signal. The modified D50 plasmid was then used to assemble a complete antigenome by ligation with a cDNA containing the L gene and trailer region as described previously (5, 33, 34). IG, intergenic region; GS, gene start signal; GE, gene end signal.

The NS2 and SH deletion viruses have been characterized with regard to their growth phenotypes in cell culture. On HEp-2 cell monolayers, D46/6368 grew slightly better than wt RSV (up to 12.6-fold higher levels) and consistently produced plaques that were 70% larger (reference 3 and data not shown), while the rA2Delta NS2 virus grew more slowly than wt RSV and produced pinpoint plaques at a titer 5- to 50-fold lower than that of wt RSV (29). When inoculated intranasally into mice, the D46/6368 virus resembled wt RSV in its level of replication in the lungs, whereas it replicated to a level 10-fold lower in the upper respiratory tract (3). Also in mice, D46/6368 and wt RSV were similar with respect to immunogenicity and efficacy in inducing resistance to RSV challenge (3). In addition, the SH gene was also deleted from the D53cp248/404 cDNA, which encodes a recombinant version of the cpts248/404 vaccine candidate. This deletion was made by replacing the SpeI-StuI cassette of D53cp248/404, which contains the SH gene, with the same cassette from the Delta SH cDNA (Fig. 1). The resulting virus, rA2cp248/404Delta SH, maintained the same level of temperature sensitivity as rA2cp248/404 and acquired a larger plaque size at the permissive temperature (data not shown). If the Delta SH and Delta NS2 mutant viruses exhibit an attenuation (att) phenotype in chimpanzees, these mutants would be of special interest for vaccine development, since it is expected that a high level of genetic stability in vitro and in vivo would be afforded by complete deletion of a viral gene. Satisfactorily attenuated and immunogenic mutants of this type might be especially safe for use in immunocompromised subjects.

The replication of the rA2Delta NS2 and rA2Delta SH deletion mutants was evaluated in a separate study with young RSV-seronegative chimpanzees according to established procedures (9), and their levels of replication and reactogenicity were compared with those of rA2 and rA2cp248/404. These findings were also compared to results from previous studies with wt RSV, which was shown to produce acute respiratory tract disease in humans and chimpanzees (7, 9, 23). Chimpanzees are the only known nonhuman host in which RSV replication and virulence approach that observed in seronegative humans. These features are indispensable for evaluation of a live attenuated RSV prior to administration to humans, particularly with mutants containing novel gene deletions. Because of the very limited number of RSV-seronegative chimpanzees available for study, the sizes of the experimental groups were small. Animals were inoculated simultaneously by the intranasal and intratracheal routes. Upper respiratory tract (nasopharyngeal swab) and lower respiratory tract (tracheal lavage) samples were collected over a period of 10 days, and the chimpanzees were monitored daily for symptoms of rhinorrhea. To compare the levels of virus replication in the animal groups, we determined the mean peak titers of infectious virus in both the upper and lower respiratory tracts. We considered differences in mean peak titers greater than 10-fold to be significant, which was confirmed statistically by the use of Duncan's Multiple Range test. Rhinorrhea scores (see Table 1, footnote d, for a definition) were also compared, and we considered scores greater than 1.0 to be significant based on extensive prior experience with this experimental model of RSV upper respiratory tract disease. The two wt viruses, RSV A2 and rA2, were comparable in their levels of virus replication and in the extents of rhinorrhea that they caused in chimpanzees (Table 1), despite the 21 nucleotide differences between the two viruses, which represent the nucleotide changes engineered into rA2 (5, 34). Since rA2 replicates and induces rhinorrhea in a manner similar to that of its biologically derived counterpart, it is an appropriate virus to compare with the rA2Delta SH and rA2Delta NS2 mutants, which are isogenic with it except for deletion of an RSV gene.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Deletion of either the NS2 or the SH gene attenuates RSV for chimpanzees

Mutant virus rA2Delta NS2 was 12.5-fold reduced in replication in the upper respiratory tract compared to rA2 (Table 1), whereas rA2Delta SH replicated to a level comparable to that of rA2. However, in the lower respiratory tract, rA2Delta NS2 and rA2Delta SH showed 10,000-fold and 40-fold reductions in replication, respectively, compared to the level of replication of rA2. In comparison with chimpanzees receiving either wt RSV A2 or rA2, chimpanzees infected with rA2Delta NS2 or rA2Delta SH exhibited less rhinorrhea. These findings demonstrate that deletion of either the NS2 or the SH gene leads to attenuation of both replication and disease symptoms in chimpanzees, with deletion of the NS2 gene having a greater effect.

Immunization with either rA2Delta NS2 or rA2Delta SH induced a high level of neutralizing antibodies that was comparable to that induced by infection with either of the wt control viruses (Table 1). Immunization with rA2Delta NS2, as with cpts248/404, induced resistance to replication of wt RSV in both the upper and lower respiratory tracts (Table 2). Taken together, these results indicated that immunization with rA2Delta NS2 was nearly as effective as immunization with mutant cpts248/404, even though cpts248/404 was administered at a fivefold higher dose. Because the Delta SH mutant D46/6368 was shown previously to induce complete protection in mice against wt RSV challenge (3), this analysis was not repeated with chimpanzees.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   Recombinant virus rA2Delta NS2 is highly protective against challenge with wt RSV A2 in the upper and lower respiratory tracts of chimpanzeesa

Vaccine candidate cpts248/404 caused a significant level of nasal congestion in a majority of vaccinees in the RSV vaccine target population of one-month-old infants, which suggests that it is incompletely attenuated for this age group (35). Therefore, more attenuated derivatives of cpts248/404 will be needed for use in very young infants. Since neither rA2Delta NS2 nor rA2Delta SH is as attenuated in chimpanzees as the incompletely attenuated rA2cp248/404 vaccine candidate, the Delta NS2 and Delta SH mutants are of interest for use in conjunction with the mutations present in rA2cp248/404. We have initiated studies designed to further attenuate cpts248/404 by the deletion of the SH gene, the less attenuating of the two deletion mutations, from rA2cp248/404. This mutation was selected for study first since the clinical evaluation of cpts248/404 in young infants indicated that only a slight increase in attenuation would be necessary to produce a satisfactory candidate vaccine and because the SH deletion was associated with a significant reduction in rhinorrhea (Table 1). The SH gene was removed from rA2cp248/404, and the resulting virus, rA2cp248/404Delta SH, was administered to chimpanzees (Table 1). Since cpts248/404 is highly attenuated in chimpanzees at a dose of 4.0 log10 PFU/ml (8), its recombinant derivatives rA2cp248/404 and rA2cp248/404Delta SH were administered at an elevated dose of 5.0 log10 PFU/ml in an attempt to augment their levels of replication to levels that would permit the detection of a difference in growth capacity. As shown in Table 1, a significant difference in levels of replication of the two viruses in the upper and lower respiratory tracts was not observed and a difference in the levels of rhinorrhea or in the neutralizing antibody responses in sera was not observed. In rA2cp248/404Delta SH, the attenuation conferred by deletion of the SH gene may be masked by the cpts248/404 att mutations. An increase in attenuation of rA2cp248/404Delta SH may be apparent only in humans, where cpts248/404 replicates to a 100-fold higher titer than in chimpanzees (35), and such studies have been initiated. Since the attenuating mutations identified in cpts248/404 are point mutations, it is hoped that the overall stability of the attenuation phenotype of rA2cp248/404 will be increased by the complete deletion of the SH gene.

Deletion of NS2 is the single most attenuating non-ts mutation we have studied to date, significantly surpassing the attenuation conferred by the cp and Delta SH mutations in both the upper and the lower respiratory tract (34). Mutant virus rA2Delta NS2 replicates slightly better than rA2cp248/404 in the upper respiratory tracts of chimpanzees, and this property suggests a possible role for it as a vaccine candidate for the elderly. To be effective, a live attenuated vaccine for this group would need to be capable of replicating and immunizing in the presence of RSV antibodies induced by prior infections and yet be sufficiently attenuated in the lower respiratory tract so as to preclude any serious reactogenicity. Because the rA2Delta NS2 virus was highly attenuated in the lower respiratory tracts of chimpanzees yet remained relatively infectious for the upper respiratory tracts, this virus may have potential use as a vaccine for a seropositive population. In addition, the feasibility of removing the NS2 gene from rA2cp248/404 and other attenuated recombinant viruses for use in the pediatric population is also under investigation in our laboratory.


    ACKNOWLEDGMENTS

We thank Robert M. Chanock and Peter F. Wright for careful reviews of the manuscript.

This work is part of a continuing program of research and development with Wyeth-Lederle Vaccines and Pediatrics through CRADA no. AI-000030 and AI-000087.


    FOOTNOTES

* Corresponding author. Mailing address: LID, NIAID, 7 Center Dr., MSC 0720, Bethesda, MD 20892-0720. Phone: (301) 496-4205. Fax: (301) 496-8312. E-mail: sswhitehead{at}nih.gov.


    REFERENCES
Top
Abstract
Text
References

1. Atreya, P. L., M. E. Peeples, and P. L. Collins. 1998. The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication. J. Virol. 72:1452-1461[Abstract/Free Full Text].
2. Bouchard, M. J., D. H. Lam, and V. R. Racaniello. 1995. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J. Virol. 69:4972-4978[Abstract].
3. Bukreyev, A., S. S. Whitehead, B. R. Murphy, and P. L. Collins. 1997. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71:8973-8982[Abstract].
4. Coates, H. V., D. W. Alling, and R. M. Chanock. 1966. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am. J. Epidemiol. 83:299-313[Free Full Text].
5. Collins, P. L., M. G. Hill, E. Camargo, H. Grosfeld, R. M. Chanock, and B. R. Murphy. 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. USA 92:11563-11567[Abstract/Free Full Text].
6. Collins, P. L., K. McIntosh, and R. M. Chanock. 1996. Respiratory syncytial virus, p. 1313-1352. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, Pa.
7. Collins, P. L., R. H. Purcell, W. T. London, L. A. Lawrence, R. M. Chanock, and B. R. Murphy. 1990. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 8:164-168[Medline].
8. Crowe, J. E., Jr., P. T. Bui, A. R. Davis, R. M. Chanock, and B. R. Murphy. 1994. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12:783-790[Medline].
9. Crowe, J. E., Jr., P. T. Bui, W. T. London, A. R. Davis, P. P. Hung, R. M. Chanock, and B. R. Murphy. 1994. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12:691-699[Medline].
10. Crowe, J. E., Jr., C. Y. Firestone, S. S. Whitehead, P. L. Collins, and B. R. Murphy. 1996. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes 13:269-273[Medline].
11. Dowell, S. F., L. J. Anderson, H. E. Gary, Jr., D. D. Erdman, J. F. Plouffe, T. M. File, Jr., B. J. Marston, and R. F. Breiman. 1996. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174:456-462[Medline].
12. Falsey, A. R., C. K. Cunningham, W. H. Barker, R. W. Kouides, J. B. Yuen, M. Menegus, L. B. Weiner, C. A. Bonville, and R. F. Betts. 1995. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 172:389-394[Medline].
13. Falsey, A. R., J. J. Treanor, R. F. Betts, and E. E. Walsh. 1992. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc. 40:115-119[Medline].
14. Firestone, C. Y., S. S. Whitehead, P. L. Collins, B. R. Murphy, and J. E. Crowe, Jr. 1996. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology 225:419-422[Medline].
15. Friedewald, W. T., B. R. Forsyth, C. B. Smith, M. A. Gharpure, and R. M. Chanock. 1968. Low-temperature-grown RS virus in adult volunteers. JAMA 203:690-694[Medline].
16. Gilchrist, S., T. J. Torok, H. E. Gary, Jr., J. P. Alexander, and L. J. Anderson. 1994. National surveillance for respiratory syncytial virus, United States, 1985-1990. J. Infect. Dis. 170:986-990[Medline].
17. Hall, C. B., K. R. Powell, N. E. MacDonald, C. L. Gala, M. E. Menegus, S. C. Suffin, and H. J. Cohen. 1986. Respiratory syncytial viral infection in children with compromised immune function. N. Engl. J. Med. 315:77-81[Abstract].
18. Hall, S. L., A. Stokes, E. L. Tierney, W. T. London, R. B. Belshe, F. C. Newman, and B. R. Murphy. 1992. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 22:173-184[Medline].
19. Harrington, R. D., T. M. Hooton, R. C. Hackman, G. A. Storch, B. Osborne, C. A. Gleaves, A. Benson, and J. D. Meyers. 1992. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J. Infect. Dis. 165:987-993[Medline].
20. Juhasz, K., S. S. Whitehead, C. A. Boulanger, C. Y. Firestone, P. L. Collins, and B. R. Murphy. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine, in press.
21. Juhasz, K., S. S. Whitehead, P. T. Bui, J. M. Biggs, C. A. Boulanger, P. L. Collins, and B. R. Murphy. 1997. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J. Virol. 71:5814-5819[Abstract].
22. La Via, W. V., M. I. Marks, and H. R. Stutman. 1992. Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention. J. Pediatr. 121:503-510[Medline].
23. Mills, J., J. E. Van Kirk, P. F. Wright, and R. M. Chanock. 1971. Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J. Immunol. 107:123-130[Abstract/Free Full Text].
24. Mlinaric-Galinovic, G., A. R. Falsey, and E. E. Walsh. 1996. Respiratory syncytial virus infection in the elderly. Eur. J. Clin. Microbiol. Infect. Dis. 15:777-781[Medline].
25. Murphy, B. R., S. L. Hall, A. B. Kulkarni, J. E. Crowe, Jr., P. L. Collins, M. Connors, R. A. Karron, and R. M. Chanock. 1994. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res. 32:13-36[Medline].
26. Murphy, B. R., E. J. Park, P. Gottlieb, and K. Subbarao. 1997. An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine 15:1372-1378[Medline].
27. Snyder, M. H., R. F. Betts, D. DeBorde, E. L. Tierney, M. L. Clements, D. Herrington, S. D. Sears, R. Dolin, H. F. Maassab, and B. R. Murphy. 1988. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J. Virol. 62:488-495[Abstract/Free Full Text].
28. Tatem, J. M., C. Weeks-Levy, A. Georgiu, S. J. DiMichele, E. J. Gorgacz, V. R. Racaniello, F. R. Cano, and S. J. Mento. 1992. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. J. Virol. 66:3194-3197[Abstract/Free Full Text].
29. Teng, M. N., and P. L. Collins. 1998. Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce the NS2 protein. J. Virol. 73:466-473[Abstract/Free Full Text].
30. Tolpin, M. D., J. G. Massicot, M. G. Mullinix, H. W. Kim, R. H. Parrott, R. M. Chanock, and B. R. Murphy. 1981. Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo. Virology 112:505-517[Medline].
31. Wendt, C. H., and M. I. Hertz. 1995. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Semin. Respir. Infect. 10:224-231[Medline].
32. Westrop, G. D., K. A. Wareham, D. M. A. Evans, G. Dunn, P. D. Minor, D. I. Magrath, F. Taffs, S. Marsden, M. A. Skinner, G. C. Schild, and J. W. Almond. 1989. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J. Virol. 63:1338-1344[Abstract/Free Full Text].
33. Whitehead, S. S., C. Y. Firestone, P. L. Collins, and B. R. Murphy. 1998. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 247:232-239[Medline].
34. Whitehead, S. S., K. Juhasz, C. Y. Firestone, P. L. Collins, and B. R. Murphy. 1998. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J. Virol. 72:4467-4471[Abstract/Free Full Text].
35. Wright, P. F. Personal communication.

Journal of Virology, April 1999, p. 3438-3442, Vol. 73, No. 4
0022-538X/99


This article has been cited by other articles:

  • Swedan, S., Musiyenko, A., Barik, S. (2009). Respiratory Syncytial Virus Nonstructural Proteins Decrease Levels of Multiple Members of the Cellular Interferon Pathways. J. Virol. 83: 9682-9693 [Abstract] [Full Text]  
  • Ling, Z., Tran, K. C., Teng, M. N. (2009). Human Respiratory Syncytial Virus Nonstructural Protein NS2 Antagonizes the Activation of Beta Interferon Transcription by Interacting with RIG-I. J. Virol. 83: 3734-3742 [Abstract] [Full Text]  
  • Song, W., Liu, G., Bosworth, C. A., Walker, J. R., Megaw, G. A., Lazrak, A., Abraham, E., Sullender, W. M., Matalon, S. (2009). Respiratory Syncytial Virus Inhibits Lung Epithelial Na+ Channels by Up-regulating Inducible Nitric-oxide Synthase. J. Biol. Chem. 284: 7294-7306 [Abstract] [Full Text]  
  • Buchholz, U. J., Ward, J. M., Lamirande, E. W., Heinze, B., Krempl, C. D., Collins, P. L. (2009). Deletion of Nonstructural Proteins NS1 and NS2 from Pneumonia Virus of Mice Attenuates Viral Replication and Reduces Pulmonary Cytokine Expression and Disease. J. Virol. 83: 1969-1980 [Abstract] [Full Text]  
  • Ling, R., Sinkovic, S., Toquin, D., Guionie, O., Eterradossi, N., Easton, A. J. (2008). Deletion of the SH gene from avian metapneumovirus has a greater impact on virus production and immunogenicity in turkeys than deletion of the G gene or M2-2 open reading frame. J. Gen. Virol. 89: 525-533 [Abstract] [Full Text]  
  • Krempl, C. D., Wnekowicz, A., Lamirande, E. W., Nayebagha, G., Collins, P. L., Buchholz, U. J. (2007). Identification of a Novel Virulence Factor in Recombinant Pneumonia Virus of Mice. J. Virol. 81: 9490-9501 [Abstract] [Full Text]  
  • Fuentes, S., Tran, K. C., Luthra, P., Teng, M. N., He, B. (2007). Function of the Respiratory Syncytial Virus Small Hydrophobic Protein. J. Virol. 81: 8361-8366 [Abstract] [Full Text]  
  • Kotelkin, A., Belyakov, I. M., Yang, L., Berzofsky, J. A., Collins, P. L., Bukreyev, A. (2006). The NS2 Protein of Human Respiratory Syncytial Virus Suppresses the Cytotoxic T-Cell Response as a Consequence of Suppressing the Type I Interferon Response.. J. Virol. 80: 5958-5967 [Abstract] [Full Text]  
  • Biacchesi, S., Pham, Q. N., Skiadopoulos, M. H., Murphy, B. R., Collins, P. L., Buchholz, U. J. (2005). Infection of Nonhuman Primates with Recombinant Human Metapneumovirus Lacking the SH, G, or M2-2 Protein Categorizes Each as a Nonessential Accessory Protein and Identifies Vaccine Candidates. J. Virol. 79: 12608-12613 [Abstract] [Full Text]  
  • Collins, P. L., Murphy, B. R. (2005). New Generation Live Vaccines against Human Respiratory Syncytial Virus Designed by Reverse Genetics. Proc Am Thorac Soc 2: 166-173 [Abstract] [Full Text]  
  • Wright, P. F., Ikizler, M. R., Gonzales, R. A., Carroll, K. N., Johnson, J. E., Werkhaven, J. A. (2005). Growth of Respiratory Syncytial Virus in Primary Epithelial Cells from the Human Respiratory Tract. J. Virol. 79: 8651-8654 [Abstract] [Full Text]  
  • Baron, M. D., Banyard, A. C., Parida, S., Barrett, T. (2005). The Plowright vaccine strain of Rinderpest virus has attenuating mutations in most genes. J. Gen. Virol. 86: 1093-1101 [Abstract] [Full Text]  
  • Asenjo, A., Rodriguez, L., Villanueva, N. (2005). Determination of phosphorylated residues from human respiratory syncytial virus P protein that are dynamically dephosphorylated by cellular phosphatases: a possible role for serine 54. J. Gen. Virol. 86: 1109-1120 [Abstract] [Full Text]  
  • Thorpe, L. C., Easton, A. J. (2005). Genome sequence of the non-pathogenic strain 15 of pneumonia virus of mice and comparison with the genome of the pathogenic strain J3666. J. Gen. Virol. 86: 159-169 [Abstract] [Full Text]  
  • Biacchesi, S., Skiadopoulos, M. H., Yang, L., Lamirande, E. W., Tran, K. C., Murphy, B. R., Collins, P. L., Buchholz, U. J. (2004). Recombinant Human Metapneumovirus Lacking the Small Hydrophobic SH and/or Attachment G Glycoprotein: Deletion of G Yields a Promising Vaccine Candidate. J. Virol. 78: 12877-12887 [Abstract] [Full Text]  
  • Naylor, C. J., Brown, P. A., Edworthy, N., Ling, R., Jones, R. C., Savage, C. E., Easton, A. J. (2004). Development of a reverse-genetics system for Avian pneumovirus demonstrates that the small hydrophobic (SH) and attachment (G) genes are not essential for virus viability. J. Gen. Virol. 85: 3219-3227 [Abstract] [Full Text]  
  • Oomens, A. G. P., Wertz, G. W. (2004). trans-Complementation Allows Recovery of Human Respiratory Syncytial Viruses That Are Infectious but Deficient in Cell-to-Cell Transmission. J. Virol. 78: 9064-9072 [Abstract] [Full Text]  
  • Elliott, M. B., Pryharski, K. S., Yu, Q., Boutilier, L. A., Campeol, N., Melville, K., Laughlin, T. S., Gupta, C. K., Lerch, R. A., Randolph, V. B., LaPierre, N. A., Dack, K. M. H., Hancock, G. E. (2004). Characterization of Recombinant Respiratory Syncytial Viruses with the Region Responsible for Type 2 T-Cell Responses and Pulmonary Eosinophilia Deleted from the Attachment (G) Protein. J. Virol. 78: 8446-8454 [Abstract] [Full Text]  
  • Elliott, M. B., Pryharski, K. S., Yu, Q., Parks, C. L., Laughlin, T. S., Gupta, C. K., Lerch, R. A., Randolph, V. B., LaPierre, N. A., Dack, K. M. H., Hancock, G. E. (2004). Recombinant Respiratory Syncytial Viruses Lacking the C-Terminal Third of the Attachment (G) Protein Are Immunogenic and Attenuated In Vivo and In Vitro. J. Virol. 78: 5773-5783 [Abstract] [Full Text]  
  • Johnson, T. R., Teng, M. N., Collins, P. L., Graham, B. S. (2004). Respiratory Syncytial Virus (RSV) G Glycoprotein Is Not Necessary for Vaccine-Enhanced Disease Induced by Immunization with Formalin-Inactivated RSV. J. Virol. 78: 6024-6032 [Abstract] [Full Text]  
  • Ramaswamy, M., Shi, L., Monick, M. M., Hunninghake, G. W., Look, D. C. (2004). Specific Inhibition of Type I Interferon Signal Transduction by Respiratory Syncytial Virus. Am. J. Respir. Cell Mol. Bio. 30: 893-900 [Abstract] [Full Text]  
  • Thoulouze, M.-I., Bouguyon, E., Carpentier, C., Bremont, M. (2004). Essential Role of the NV Protein of Novirhabdovirus for Pathogenicity in Rainbow Trout. J. Virol. 78: 4098-4107 [Abstract] [Full Text]  
  • Easton, A. J., Domachowske, J. B., Rosenberg, H. F. (2004). Animal Pneumoviruses: Molecular Genetics and Pathogenesis. Clin. Microbiol. Rev. 17: 390-412 [Abstract] [Full Text]  
  • Tran, K. C., Collins, P. L., Teng, M. N. (2004). Effects of Altering the Transcription Termination Signals of Respiratory Syncytial Virus on Viral Gene Expression and Growth In Vitro and In Vivo. J. Virol. 78: 692-699 [Abstract] [Full Text]  
  • Bossert, B., Marozin, S., Conzelmann, K.-K. (2003). Nonstructural Proteins NS1 and NS2 of Bovine Respiratory Syncytial Virus Block Activation of Interferon Regulatory Factor 3. J. Virol. 77: 8661-8668 [Abstract] [Full Text]  
  • Valarcher, J.-F., Furze, J., Wyld, S., Cook, R., Conzelmann, K.-K., Taylor, G. (2003). Role of Alpha/Beta Interferons in the Attenuation and Immunogenicity of Recombinant Bovine Respiratory Syncytial Viruses Lacking NS Proteins. J. Virol. 77: 8426-8439 [Abstract] [Full Text]  
  • Schlender, J., Zimmer, G., Herrler, G., Conzelmann, K.-K. (2003). Respiratory Syncytial Virus (RSV) Fusion Protein Subunit F2, Not Attachment Protein G, Determines the Specificity of RSV Infection. J. Virol. 77: 4609-4616 [Abstract] [Full Text]  
  • Oomens, A. G. P., Megaw, A. G., Wertz, G. W. (2003). Infectivity of a Human Respiratory Syncytial Virus Lacking the SH, G, and F Proteins Is Efficiently Mediated by the Vesicular Stomatitis Virus G Protein. J. Virol. 77: 3785-3798 [Abstract] [Full Text]  
  • Young, D. F., Andrejeva, L., Livingstone, A., Goodbourn, S., Lamb, R. A., Collins, P. L., Elliott, R. M., Randall, R. E. (2003). Virus Replication in Engineered Human Cells That Do Not Respond to Interferons. J. Virol. 77: 2174-2181 [Abstract] [Full Text]  
  • Neumann, G., Whitt, M. A., Kawaoka, Y. (2002). A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?. J. Gen. Virol. 83: 2635-2662 [Abstract] [Full Text]  
  • Krempl, C., Murphy, B. R., Collins, P. L. (2002). Recombinant Respiratory Syncytial Virus with the G and F Genes Shifted to the Promoter-Proximal Positions. J. Virol. 76: 11931-11942 [Abstract] [Full Text]  
  • Zimmer, G., Conzelmann, K.-K., Herrler, G. (2002). Cleavage at the Furin Consensus Sequence RAR/KR109 and Presence of the Intervening Peptide of the Respiratory Syncytial Virus Fusion Protein Are Dispensable for Virus Replication in Cell Culture. J. Virol. 76: 9218-9224 [Abstract] [Full Text]  
  • Teng, M. N., Collins, P. L. (2002). The Central Conserved Cystine Noose of the Attachment G Protein of Human Respiratory Syncytial Virus Is Not Required for Efficient Viral Infection In Vitro or In Vivo. J. Virol. 76: 6164-6171 [Abstract] [Full Text]  
  • Bossert, B., Conzelmann, K.-K. (2002). Respiratory Syncytial Virus (RSV) Nonstructural (NS) Proteins as Host Range Determinants: a Chimeric Bovine RSV with NS Genes from Human RSV Is Attenuated in Interferon-Competent Bovine Cells. J. Virol. 76: 4287-4293 [Abstract] [Full Text]  
  • Schmidt, A. C., Wenzke, D. R., McAuliffe, J. M., St. Claire, M., Elkins, W. R., Murphy, B. R., Collins, P. L. (2002). Mucosal Immunization of Rhesus Monkeys against Respiratory Syncytial Virus Subgroups A and B and Human Parainfluenza Virus Type 3 by Using a Live cDNA-Derived Vaccine Based on a Host Range-Attenuated Bovine Parainfluenza Virus Type 3 Vector Backbone. J. Virol. 76: 1089-1099 [Abstract] [Full Text]  
  • Techaarpornkul, S., Barretto, N., Peeples, M. E. (2001). Functional Analysis of Recombinant Respiratory Syncytial Virus Deletion Mutants Lacking the Small Hydrophobic and/or Attachment Glycoprotein Gene. J. Virol. 75: 6825-6834 [Abstract] [Full Text]  
  • Zimmer, G., Trotz, I., Herrler, G. (2001). N-Glycans of F Protein Differentially Affect Fusion Activity of Human Respiratory Syncytial Virus. J. Virol. 75: 4744-4751 [Abstract] [Full Text]  
  • Karger, A., Schmidt, U., Buchholz, U. J. (2001). Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin. J. Gen. Virol. 82: 631-640 [Abstract] [Full Text]  
  • Bukreyev, A., Murphy, B. R., Collins, P. L. (2000). Respiratory Syncytial Virus Can Tolerate an Intergenic Sequence of at Least 160 Nucleotides with Little Effect on Transcription or Replication In Vitro and In Vivo. J. Virol. 74: 11017-11026 [Abstract] [Full Text]  
  • Hallak, L. K., Spillmann, D., Collins, P. L., Peeples, M. E. (2000). Glycosaminoglycan Sulfation Requirements for Respiratory Syncytial Virus Infection. J. Virol. 74: 10508-10513 [Abstract] [Full Text]  
  • Cuesta, I., Geng, X., Asenjo, A., Villanueva, N. (2000). Structural Phosphoprotein M2-1 of the Human Respiratory Syncytial Virus Is an RNA Binding Protein. J. Virol. 74: 9858-9867 [Abstract] [Full Text]  
  • Teng, M. N., Whitehead, S. S., Bermingham, A., St. Claire, M., Elkins, W. R., Murphy, B. R., Collins, P. L. (2000). Recombinant Respiratory Syncytial Virus That Does Not Express the NS1 or M2-2 Protein Is Highly Attenuated and Immunogenic in Chimpanzees. J. Virol. 74: 9317-9321 [Abstract] [Full Text]  
  • Schlender, J., Bossert, B., Buchholz, U., Conzelmann, K.-K. (2000). Bovine Respiratory Syncytial Virus Nonstructural Proteins NS1 and NS2 Cooperatively Antagonize Alpha/Beta Interferon-Induced Antiviral Response. J. Virol. 74: 8234-8242 [Abstract] [Full Text]  
  • Bukreyev, A., Whitehead, S. S., Prussin, C., Murphy, B. R., Collins, P. L. (2000). Effect of Coexpression of Interleukin-2 by Recombinant Respiratory Syncytial Virus on Virus Replication, Immunogenicity, and Production of Other Cytokines. J. Virol. 74: 7151-7157 [Abstract] [Full Text]  
  • Tao, T., Skiadopoulos, M. H., Davoodi, F., Riggs, J. M., Collins, P. L., Murphy, B. R. (2000). Replacement of the Ectodomains of the Hemagglutinin-Neuraminidase and Fusion Glycoproteins of Recombinant Parainfluenza Virus Type 3 (PIV3) with Their Counterparts from PIV2 Yields Attenuated PIV2 Vaccine Candidates. J. Virol. 74: 6448-6458 [Abstract] [Full Text]  
  • Matthews, J. M., Young, T. F., Tucker, S. P., Mackay, J. P. (2000). The Core of the Respiratory Syncytial Virus Fusion Protein Is a Trimeric Coiled Coil. J. Virol. 74: 5911-5920 [Abstract] [Full Text]  
  • Buchholz, U. J., Granzow, H., Schuldt, K., Whitehead, S. S., Murphy, B. R., Collins, P. L. (2000). Chimeric Bovine Respiratory Syncytial Virus with Glycoprotein Gene Substitutions from Human Respiratory Syncytial Virus (HRSV): Effects on Host Range and Evaluation as a Live-Attenuated HRSV Vaccine. J. Virol. 74: 1187-1199 [Abstract] [Full Text]  
  • Jin, H., Cheng, X., Zhou, H. Z. Y., Li, S., Seddiqui, A. (2000). Respiratory Syncytial Virus That Lacks Open Reading Frame 2 of the M2 Gene (M2-2) Has Altered Growth Characteristics and Is Attenuated in Rodents. J. Virol. 74: 74-82 [Abstract] [Full Text]  
  • Whitehead, S. S., Hill, M. G., Firestone, C. Y., St. Claire, M., Elkins, W. R., Murphy, B. R., Collins, P. L. (1999). Replacement of the F and G Proteins of Respiratory Syncytial Virus (RSV) Subgroup A with Those of Subgroup B Generates Chimeric Live Attenuated RSV Subgroup B Vaccine Candidates. J. Virol. 73: 9773-9780 [Abstract] [Full Text]  
  • Bermingham, A., Collins, P. L. (1999). The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc. Natl. Acad. Sci. USA 96: 11259-11264 [Abstract] [Full Text]  
  • Zimmer, G., Budz, L., Herrler, G. (2001). Proteolytic Activation of Respiratory Syncytial Virus Fusion Protein. CLEAVAGE AT TWO FURIN CONSENSUS SEQUENCES. J. Biol. Chem. 276: 31642-31650 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whitehead, S. S.
Right arrow Articles by Murphy, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitehead, S. S.
Right arrow Articles by Murphy, B. R.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»